Literature DB >> 15956372

Outbreak of dysentery associated with ceftriaxone-resistant Shigella sonnei: First report of plasmid-mediated CMY-2-type AmpC beta-lactamase resistance in S. sonnei.

I-Fei Huang1, Cheng-Hsun Chiu, Mei-Hui Wang, Chan-Yao Wu, Kai-Sheng Hsieh, Christine C Chiou.   

Abstract

We document the first report of plasmid-encoded CMY-2-type AmpC beta-lactamase identified among Shigella sonnei isolates resistant to ceftriaxone and obtained after an outbreak of bacillary dysentery in Taiwan. One hundred eighty-two children in two elementary schools in Yu-Li, Taiwan, where an outbreak occurred after a typhoon hit this area in 2001, were enrolled in this study. Clinical and epidemiologic data on the infected children were collected. Pulsed-field gel electrophoresis (PFGE) was performed on the isolates to determine the genetic relatedness of outbreak strains. Plasmid analysis and PCR were performed to identify beta-lactamase genes responsible for ceftriaxone resistance. Forty-seven children from the two elementary schools were culture positive for S. sonnei in this outbreak. Twenty-three children were asymptomatic. Of the total isolates 55.3% were resistant to ampicillin. One hundred percent of the isolates obtained from children in school A were initially susceptible to both ampicillin and ceftriaxone. Of isolates obtained from school B 96.2% were nonsusceptible to ceftriaxone. However, two isolates from school A developed resistance to ampicillin during the course of treatment. All 18 available isolates showed closely related PFGE patterns (4, 4a, 4b, and 4c). CMY-2-type AmpC beta-lactamase was responsible for ceftriaxone resistance in ceftriaxone-nonsusceptible isolates; Southern blot hybridization confirmed that such a resistance gene was located on the plasmid. This is the first report of plasmid-mediated CMY-2-type AmpC beta-lactamase in S. sonnei. Ampicillin-resistant isolates can develop during the course of antibiotic treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956372      PMCID: PMC1151904          DOI: 10.1128/JCM.43.6.2608-2612.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Identification of CTX-M-14 extended-spectrum beta-lactamase in clinical isolates of Shigella sonnei, Escherichia coli, and Klebsiella pneumoniae in Korea.

Authors:  H Pai; E H Choi; H J Lee; J Y Hong; G A Jacoby
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

2.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

3.  SHV-type extended-spectrum beta-lactamase in a Shigella flexneri clinical isolate.

Authors:  N Fortineau; T Naas; O Gaillot; P Nordmann
Journal:  J Antimicrob Chemother       Date:  2001-05       Impact factor: 5.790

4.  Rapid procedure for detection and isolation of large and small plasmids.

Authors:  C I Kado; S T Liu
Journal:  J Bacteriol       Date:  1981-03       Impact factor: 3.490

5.  beta-lactamases in Shigella flexneri isolates from Hong Kong and Shanghai and a novel OXA-1-like beta-lactamase, OXA-30.

Authors:  L K Siu; J Y Lo; K Y Yuen; P Y Chau; M H Ng; P L Ho
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

6.  Typing and characterization of mechanisms of resistance of Shigella spp. isolated from feces of children under 5 years of age from Ifakara, Tanzania.

Authors:  M M Navia; L Capitano; J Ruiz; M Vargas; H Urassa; D Schellemberg; J Gascon; J Vila
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

7.  CTX-M-3 extended-spectrum beta-lactamase in a Shigella sonnei clinical isolate: first report from Turkey.

Authors:  Ziya Cibali Acikgoz; Zeynep Gulay; Meral Bicmen; Safiye Gocer; Sohret Gamberzade
Journal:  Scand J Infect Dis       Date:  2003

8.  Characterization of plasmids from antibiotic-resistant Shigella isolates by agarose gell electrophoresis.

Authors:  A F Jamieson; D A Bremner; P L Bergquist; H E Lane
Journal:  J Gen Microbiol       Date:  1979-07

9.  Case-control study of endemic diarrheal disease in Thai children.

Authors:  P Echeverria; D N Taylor; U Lexsomboon; M Bhaibulaya; N R Blacklow; K Tamura; R Sakazaki
Journal:  J Infect Dis       Date:  1989-03       Impact factor: 5.226

10.  Third-generation cephalosporin resistance in Shigella sonnei, Argentina.

Authors:  M Radice; C Gonzéález; P Power; M C Vidal; G Gutkind
Journal:  Emerg Infect Dis       Date:  2001 May-Jun       Impact factor: 6.883

View more
  26 in total

1.  High prevalence of antimicrobial resistance among Shigella isolates in the United States tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002.

Authors:  Sumathi Sivapalasingam; Jennifer M Nelson; Kevin Joyce; Mike Hoekstra; Frederick J Angulo; Eric D Mintz
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Shigellosis in Bay of Bengal Islands, India: clinical and seasonal patterns, surveillance of antibiotic susceptibility patterns, and molecular characterization of multidrug-resistant Shigella strains isolated during a 6-year period from 2006 to 2011.

Authors:  D Bhattacharya; H Bhattacharya; R Thamizhmani; D S Sayi; R Reesu; M Anwesh; C Kartick; A P Bharadwaj; M Singhania; A P Sugunan; S Roy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-29       Impact factor: 3.267

Review 3.  Shigella flexneri: an emerging pathogen.

Authors:  Iqbal Nisa; Muhammad Qasim; Nusrat Yasin; Rafi Ullah; Anwar Ali
Journal:  Folia Microbiol (Praha)       Date:  2020-02-05       Impact factor: 2.099

4.  The molecular characteristics of cefepime-susceptible Escherichia coli and Klebsiella spp. isolates with a positive β-lactamase screening test result but negative confirmation.

Authors:  F Hu; W Wu; X Ye; X Xu; D Zhu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-13       Impact factor: 3.267

5.  A Waterborne Outbreak of Shigella sonnei with Resistance to Azithromycin and Third-Generation Cephalosporins in China in 2015.

Authors:  Qiuxia Ma; Xuebin Xu; Ming Luo; Jian Wang; Chaojie Yang; Xiaofeng Hu; Beibei Liang; Fuli Wu; Xiaoxia Yang; Jinyan Wang; Hongbo Liu; Wen Li; Yu Zhong; Peng Li; Jing Xie; Leili Jia; Ligui Wang; Rongzhang Hao; Xinying Du; Shaofu Qiu; Hongbin Song; Yansong Sun
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

6.  Antimicrobial resistance among Salmonella and Shigella isolates in five Canadian provinces (1997 to 2000).

Authors:  Leah J Martin; James Flint; André Ravel; Lucie Dutil; Kathryn Doré; Marie Louie; Frances Jamieson; Sam Ratnam
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-07       Impact factor: 2.471

7.  blaCMY-2-positive IncA/C plasmids from Escherichia coli and Salmonella enterica are a distinct component of a larger lineage of plasmids.

Authors:  Douglas R Call; Randall S Singer; Da Meng; Shira L Broschat; Lisa H Orfe; Janet M Anderson; David R Herndon; Lowell S Kappmeyer; Joshua B Daniels; Thomas E Besser
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

8.  Role of ceftiofur in selection and dissemination of blaCMY-2-mediated cephalosporin resistance in Salmonella enterica and commensal Escherichia coli isolates from cattle.

Authors:  Joshua B Daniels; Douglas R Call; Dale Hancock; William M Sischo; Katherine Baker; Thomas E Besser
Journal:  Appl Environ Microbiol       Date:  2009-04-17       Impact factor: 4.792

Review 9.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

10.  Increasing spectrum in antimicrobial resistance of Shigella isolates in Bangladesh: resistance to azithromycin and ceftriaxone and decreased susceptibility to ciprofloxacin.

Authors:  Mahbubur Rahman; Shereen Shoma; Harunur Rashid; Shams El Arifeen; A H Baqui; A K Siddique; G B Nair; D A Sack
Journal:  J Health Popul Nutr       Date:  2007-06       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.